Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

06-042025

Poster: Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Download Poster_Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with plat...
05-272025

Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

Guangzhou and London – May 22, 2025) Injection, a biosimilarreferencing Stelara® (ustekinumab) Injection. STARJEMZA® is ...
04-142025

Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Guangzhou, China– April 14, 2025 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeve...

上一页 ···5 6 7 8 9 ··· 下一页